This is the property of 2016 CRIT/FIT. Permission is required to duplicate.

# Opioids and Chronic Pain

CRIT/FIT 2016

#### April 2016

Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education (CARE) Unit





Boston University School of Medicine



## **Chronic Pain in Perspective**

- 100 Million in U.S. with chronic pain
  - 25 million have moderate to severe chronic pain



### Chronic pain can be a disease in itself

- Pathologic, maladaptive disorders of somatosensory pain signaling pathways that persists well after the acute injury
- Management approaches designed for acute, self-limited pain are inadequate and inappropriate for treating chronic pain

Institute of Medicine. 2011 Relieving Pain in America. Washington DC Dzau VJ, Pizzo PA. *JAMA* 2014 Walk D, Poliak-Tunis M. *Med Clin N Am*. 2016

## **Chronic Pain in Perspective**

- Significant barriers to adequate pain care
  - Negative attitudes and disparities in pain care
  - Lack of decision support for chronic pain management
  - Financial misalignment favoring use of medications
  - Over-burdened primary care providers

# Care must be tailored to each patient's experience

Institute of Medicine. 2011 Relieving Pain in America. Washington DC Reuben DB et al. *Ann Intern Med*. 2015



## **Worrisome Trends and Associations**



MMWR Nov 4, 2011 Volkow ND et al. *N Engl J Med*. 2014 Tolia VN et al. *N Engl J Med*. 2015

### "The pain medication conundrum"

#### **Opinion** The New York Times

- Undertreating pain, we are admonished...it violates the basic ethical principles of medicine. On the other hand, we are lambasted for overprescribing pain medications... creating an epidemic of overdose deaths.
- For patients with chronic pain, especially those with syndromes that don't fit into neat clinical boxes, being judged by doctors to see if they "merit" medication is humiliating and dispiriting. This type of judgment, with its moral overtones and suspicions, is at odds with the doctor-patient relationship we work to develop.

"As Mr. W. and I sat there sizing each other up, I could feel our reserves of trust beginning to ebb. I was debating whether his pain was real or if he was trying to snooker me. He was most likely wondering whether I would believe him..."

Danielle Ofri, MD Associate Professor at NYU and a physician at Bellevue Hospital *August 2015* 

### "My chronic pain isn't a crime"

#### Opinion The Boston Globe

- I will be in chronic pain until I die...I accept it.
- Pain medication is inadequate. But with it I am more consistently functional (homeowner, spouse, parent, teacher, writer, editor).
- Abuse of prescription pain medications is a serious problem; people are dying.
- Ever-tighter regulations...are of dubious value in reducing [abuse] while causing grave harm to those of us in chronic pain, to the overwhelming majority who take medications for appropriate reasons.

"Increasingly I am a suspect, treated less as a patient and more as a criminal."

Donald N.S. Unger, MFA, PhD Visiting Lecturer English Department, College of the Holy Cross *February 2015* 

### **Opioids in Perspective**

- The efficacy and safety of chronic opioid therapy for chronic pain has been inadequately studied\*
- Opioid prescribing needs to be more selective and conservative
- Opioids for chronic pain...
  - help some patients
  - harm some patients
  - are only one tool for managing severe chronic pain
  - are indicated only when alternative safer treatment options are inadequate
     \* Chou B et al. Ann Intern Med 2015

Chou R et al. *Ann Intern Med*Dowell D et al. *JAMA*Manchikanti L et al. *Pain Physician*Reuben DB et al. *Ann Intern Med*Volkow ND, McLellan T. *N Engl J Med*

### **Multidimensional Care**



## **Building Trust**

After you take a thorough pain history...

Show empathy for patient experience Discuss factors which worsen pain and limit treatment (i.e. substance use, mental health)

Validate that you believe pain is real

Believing a patient's pain complaint does not mean opioids are indicated

### **Opioid Efficacy for Chronic Pain**

- Most literature: surveys and uncontrolled case series
- RCTs are short duration (<8 months) with small samples (<300 patients)</li>
- Mostly pharmaceutical company sponsored
- Outcomes
  - Better analgesia with opioids vs. placebo
  - Pain relief modest
  - Mixed reports on function
  - Addiction not assessed

Ballantyne JC, Mao J. *N Engl J Med*. 2003 Chou R et al. *Ann Intern Med*. 2015 Eisenberg E, McNicol ED, Carr DB. *JAMA*. 2005 Furlan AD, et al. *CMAJ*. 2006 Kelso E, et al. *Pain.*Martell BA, et al. *Ann Intern Med.*Michna E, et al. *Pain Med*Noble M, et al. *Cochrane Systematic Reviews*. 2010.

### **Opioid Efficacy for Chronic Pain**

- Proportion of patients with at least 50% pain relief
- N = 442
- Follow-up 7.5 months (mean) to 13 months (1<sup>2</sup> 77.3%)

Study Name	Event Rate	Lower Limit	Upper Limit	Total	Proportion
Zenz 1992	0.510	0.413	0.606	51/100	+
Allan 2005	0.392	0.341	0.445	134 / 342	+
	0.443	0.333	0.559		
					0 00 0 50 1 00

#### 44.3% of participants had at least 50% pain relief

Noble M et al. Cochrane Systematic Reviews 2010.

### Variable Response to Opioids

#### **Mu-opioid Receptor**

- >100 polymorphisms in the human MOR gene
- Mu-opioid receptor subtypes

#### **Opioid Pharmacokinetics**

 Opioid metabolism differs by individual opioid and by individual patient

# Not all patients respond to the same opioid in the same way

## **Opioid Safety and Risks**

- Allergies are rare
- Side effects are common
  - Nausea, sedation, constipation, urinary retention, sweating
  - Respiratory depression sleep apnea
- Organ toxicities are rare
  - Suppression of hypothalamic-pituitary-gonadal axis
- Worsening pain (hyperalgesia in some patients)
- Addiction
- Overdose
  - when combined w/ other sedatives
  - at high doses

Dunn KM et al. Ann Intern Med 2010 Li X et al. Brain Res Mol Brain Res 2001 Doverty M et al. Pain 2001 Angst MS, Clark JD. Anesthesiology 2006

## **Dose and Overdose Risk**



Group Health Consort Study, 1997-2005; Dunn KM, et al. Ann Intern Med. 2010

### **Rates of Problematic Opioid Use in Chronic Pain**

Systematic review from 38 studies (26% primary care settings, 53% pain clinics)

#### Misuse rates: 21% - 29% ([95%CI]: 13%-38%)

**Misuse:** Opioid use contrary to the directed or prescribed pattern of use, regardless of the presence or absence of harm or adverse effects.

#### Addiction rates: 8% - 12% ([95% CI]: 3%-17%)

**Addiction:** Pattern of continued use with experience of, or demonstrated potential for, harm (eg, "impaired control over drug use, compulsive use, continued use despite harm, and craving").

Vowles KE et al. Pain. 2015

## **Opioid Misuse Risk**

#### Known Risk Factors

Good Predictors for Prescription -Opioid Misuse

- Young age (less than 45 years)
- Personal history of substance use disorder
  Illicit, prescription, alcohol, nicotine
- Family history of substance use disorder
- Legal history
  - DUI, incarceration
- Mental health problems
- History of sexual abuse

Akbik H, et al. *J Pain Symptom Manage*. 2006 Ives J, et al. *BMC Health Serv Res*. 2006 Liebschutz JM, et al. *J Pain*. 2010 Michna E, et al. *J Pain Symptom Manage*. 2004 Reid MC, et al. *J Gen Intern Med*. 2002



## Does my patient have an OUD?

- ✓ \*Tolerance
- ✓ \*Withdrawal
- ✓ Use in larger amounts or duration than intended
- ✓ Persistent desire to cut down
- ✓ Giving up interests to use opioids
- Great deal of time spent
  obtaining, using, or recovering
  from opioids

\*This criterion is not considered to be met for those individuals taking opioids solely under appropriate medical supervision

- Craving or strong desire to use opioids
- ✓ Recurrent use resulting in failure to fulfill major role obligations
- ✓ Recurrent use in hazardous situations
- ✓ Continued use despite social or interpersonal problems caused or exacerbated by opioids
- Continued use despite physical or psychological problems

Mild OUD: 2-3 Criteria Moderate OUD: 4-5 Criteria Severe OUD: <u>></u>6 Criteria

American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.)

## Is the my patient addicted?

**Clinical syndrome presenting as...** 

- Loss of **C**ontrol
- Compulsive use
- **Continued use despite harm**
- Aberrant Medication Taking Behaviors (pattern and severity)

Addiction is a behavioral maladaptation
 Physical Dependence is a biologic adaptation

Savage SR, et al. J Pain Symptom Manage. 2003

### **Aberrant Medication Taking Behaviors** *The Spectrum of Severity*

Requests for increase opioid dose

Requests for specific opioid by name, "brand name only"

## **Aberrant Medication-Taking Behaviors**

#### **Differential Diagnosis (DDx)**

#### Pain Relief Seeking

- Disease progression
- Poorly opioid responsive pain
- Withdrawal mediated pain
- Opioid analgesic tolerance
- Opioid-induced hyperalgesia



#### **Drug Seeking**

- Opioid use disorder/Addiction
- Other psychiatric diagnosis
- Criminal intent (diversion)

## When Are Opioids Indicated?

- Pain is moderate to severe
- Pain has significant impact on function and quality of life
- Non-opioid pharmacotherapy has been tried and failed
- Patient agreeable to...
  - take opioids exactly as prescribed
    - e.g., no unsanctioned dose escalation
  - have opioid use closely monitored
    - e.g. pill counts, urine drug testing



## "Universal Precautions"

(not evidence-based but has become "standard" of care)

- Agreements "contracts", informed consent
- Monitor for benefit and harm with frequent face-toface visits
- Monitor for adherence, addiction and diversion
  - Urine drug testing
  - Pill counts
  - Prescription monitoring program data

FSMB Guidelines 2004 www.fsmb.org Gourlay DL, Heit HA. Pain Medicine 2005 Chou R et al. J Pain 2009

## What is the physician's role?



Nicolaidis C. Pain Medicine 2011

#### **Implementing Universal Precautions in Pain Medicine**

#### Use a Health-Oriented, Risk Benefit Framework

### **NOT...**

- Is the patient good or bad?
- Does the patient deserve opioids?
- Should this patient be punished or rewarded?
- Should I trust the patient?

### RATHER...

Do the benefits of opioid treatment outweigh the untoward effects and risks for this patient (or society)?

## Judge the opioid treatment NOT the patient

## **Assessing Benefit: PEG scale**

1. Wha	at num	nber be	est des	cribes	s your	<u>pain o</u>	n aver	<u>age</u> in	the pa	ast week:
0	1	2	3	4	5	6	7	8	9	10
Nop	bain									Pain as bad as you can imagine
2. Wh with y	2. What number best describes how, during the past week, pain has interfered with your <u>enjoyment of life</u> ?									
0	1	2	3	4	5	6	7	8	9	10
Doe inter	s not fere									Completely interferes
3. What number best describes how, during the past week, pain has interfered with your <u>general activity</u> ?										
0	1	2	3	4	5	6	7	8	9	10
Doe inter	s not fere									Completely interferes

Krebs EE, et al. J Gen Intern Med. 2009

## **Assessing Risk: Opioid Risk Tool**

	Female	Male	
Family history of substance abuse			
Alcohol	<b>D</b> 1	□3	
Illegal drugs	2	□3	
Prescription drugs	□4	<b>4</b>	
Personal history of substance abuse			
Alcohol	□3	□3	
Illegal drugs	4	<b>4</b>	
Prescription drugs	□5	⊒5	
Age between 16-45 years	<b>D</b> 1	<b>D</b> 1	
History of preadolescent sexual abuse	□3	0	
Psychological disease			Scoring
ADHD, OCD, bipolar, schizophrenia	2	2	4-7 moderate risk
Depression	<b>D</b> 1	<b>D</b> 1	>8 high risk

Webster LR, Webster RM. Pain Medicine, 2006

## **Discussing Monitoring with Patients**

- Discuss risks of opioid medications
- Responsibility to look for early signs of harm
- Discuss agreements, pill counts, drug tests, etc. as ways that you are helping to protect patient from getting harmed by medications

#### Use consistent approach (Universal Precautions) BUT apply it individually to match risk

### **Urine Drug Testing**

Objective information that can provide:

- Evidence of therapeutic adherence
- Evidence of use or non-use of illicit drugs
- Discuss urine drug testing openly with patient
  - If I send your urine right now, what will I find in it...
- Document time of last medication use
- One medical data point to integrate with others
  - Cannot discriminate elective use, addictive use and diversion
- Dedicated deceivers can beat the system

### **Urine Drug Testing**

- Urine drug screens are usually immunoassays
  - Quick and relatively inexpensive
  - Need to know what is included in testing panel
  - Risk of false negatives due to cut offs
  - Risk of false positives due to cross reactions
  - Unexpected findings can be verified with Gas Chromatography/Mass Spectroscopy (GC/MS)

Identify a toxicologist/clinical pathologist for questions regarding unexpected results

### **Urine Drug Testing**

### GC/MS confirmation

- Identifies specific molecules sensitive and specific but more expensive
- Measurement of urine drug levels is not a valid method of determining the amount of opioid ingested
- Understand opioid metabolism to interpret GC/MS results



Peppin JF, et al. *Pain Med.* 2012

Heit HA, Gourlay DL. J Pain Symptom Manage. 2004

Heit HA, et al. <u>Urine Drug</u> <u>Testing in Clinical Practice;</u> Pharmacom Group Inc., May 2010.

Reisfield GM, et al. *Bioanalysis.* 2009

### **Pill Counts**

Objective information that can:

- Confirm medication adherence
- Minimize diversion

Strategy	28 day supply (rather than 30 days) prevents running out on weekends				
	Prescribe so that patient should have residual medication at appointments				
	Ask patient to bring in medications at each visit				
	For identified risks or concerns, can request random call-backs for immediate counts				

### Prescription Drug Monitoring Programs (PDMP)

 Statewide electronic database on dispensed controlled substance prescriptions



- Prescription data available to prescribers and pharmacists (usually for the past year, and including information on date dispensed, patient, prescriber, pharmacy, medicine, and dose)
- A substantially underutilized resource
  - Many states now mandate use before writing for controlled substances
- Several studies suggest association between PDMP use and positive outcomes related to improving prescribing and reducing prescription drug abuse

www.pdmpexcellence.org/sites/all/pdfs/Brandeis\_PDMP\_Report.pdf Haffajee RL, et al. JAMA. 2015

## **Continuation of Opioids**

- Before writing the next prescription...you should be convinced that...
  - ...there is benefit (pain, function, QOL)
  - ...benefits outweigh observed harms/risks

## **Discontinuing Opioids**

- Do not have to prove addiction or diversion only assess and reassess the risk-benefit ratio
- If patient is unable to take opioids safely or is nonadherent with monitoring then discontinuing opioids is appropriate even in setting of benefits
- Need to determine how urgent the discontinuation should be based on the severity of the risks and harms
- Document rationale for discontinuing opioids

# You are abandoning the opioid therapy <u>NOT</u> the patient

## **Using Risk Benefit Framework**



#### **Useful to Avoid Pitfalls...**

- "But I really, really need opioids."
- "I thought we had a good relationship/I thought you cared about me."
- "If you don't give them to me, I will drink/use drugs/hurt myself."
- "Can you just give me enough to find a new doc?"

#### **RESPONSE:**

"I cannot a prescribe a medication that is not helping you (or is hurting you)."

## Summary

- Opioids can be effective and safe but are imperfect
- Use risk/harm benefit framework
- Use consistent approach, but set level of monitoring to match risk
- Judge the treatment and not the patient
- If there is benefit in the absence of harm, continue opioids
- If there is no benefit or if there is harm, discontinue opioids